MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
American Heart Journal
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,105 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,105 works in the cohort · of 4,299,418page 11 of 23

Labels cover 0 of 1,105 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,105 of 1,105 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial
Thomas J. Povsic, Mauricio G. Cohen, Roxana Mehran, Christopher E. Buller, Christoph Bode, Jan H. Cornel +8 more
2011· article· en· American Heart Journal· Medicine
machine prediction:candidate · noneconsensus · none
36
citations
affno abstractunlabeled
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial
José Carlos Nicolau, Deepak L. Bhatt, Matthew T. Roe, Yuliya Lokhnygina, Benjamin Neely, Ramón Corbalán +10 more
2015· article· en· American Heart Journal· Medicine
machine prediction:candidate · noneconsensus · none
36
citations
affno abstractunlabeled
Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy
Philippe Gabríel Steg, Shamir R. Mehta, Charles V. Pollack, Christoph Bode, Christophe Gaudin, Karen Fanouillere +3 more
2012· article· en· American Heart Journal· Medicine
machine prediction:candidate · noneconsensus · none
35
citations
aboutno affno abstractunlabeled
Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: The G-CSF in Angina patients with IHD to stimulate Neovascularization (GAIN I) trial
Jason C. Kovacic, Peter S. Macdonald, Michael P. Feneley, David W.M. Muller, Judith Freund, Anthony J. Dodds +6 more
2008· article· en· American Heart Journal· Medicine
machine prediction:candidate · noneconsensus · none
34
citations

How this was built: Screen · Findings · About